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Introduction {#sec1}
============

Dengue virus (DENV) is a single-stranded positive sense RNA virus. It is estimated that over one-third of the world's population is at risk for DENV infection, resulting in almost 400 million infections annually ([@bib2]). Infection with DENV can result in a range of symptoms, from subclinical or mild disease, to severe DENV hemorrhagic disease and shock syndrome ([@bib21], [@bib26]). There are four genetically and antigenically distinct DENV serotypes (DENV1--DENV4), which co-circulate around the world ([@bib52], [@bib6], [@bib24]). Infection with one serotype is thought to provide long-term protection against subsequent infection with the homologous serotype; however, individuals are at risk for infection with the remaining three serotypes ([@bib10]). However, there are rare instances of reinfection with the homologous serotype ([@bib17], [@bib51]), suggesting that homotypic immunity may fail to prevent infection under some conditions ([@bib25]).

The four DENV serotypes share approximately 80% homology at an amino acid level across the entire coding region of the genome ([@bib16]). The envelope glycoprotein is roughly 70% conserved across DENV1--DENV4, containing fully conserved regions with no variation (e.g., fusion loop), and other regions containing highly divergent sequences ([@bib41]). The molecular and evolutionary drivers of variation between and within serotypes remains uncertain ([@bib1], [@bib24]). As determined using phylogenetic analyses, within each serotype, there are multiple genetically distinct genotypes, which are more closely related to each other than they are to the other serotypes ([@bib52]).

DENV4 was first reported in the Philippines and Thailand in 1953, has since spread worldwide, and currently co-circulates with DENV1--DENV3 ([@bib33]). Within DENV4, there are five distinct genotypes (I, II, III, IV, and V) with genotype II being further divided into IIa and IIb ([Figure 1](#fig1){ref-type="fig"}) ([@bib8]). Genotypes I and II currently circulate in human populations throughout the world ([@bib7], [@bib11], [@bib15], [@bib28]). Conversely, genotype III, IV, and V infections are relatively rare. Genotype III has been detected sporadically in Asia between 1997 and 2015, and genotype V was primarily detected in India in the 1960s, but has been detected as recently as 2009 ([@bib28], [@bib53], [@bib45]). Genotype IV is sylvatic, with only three known sequences ([@bib14], [@bib43]), and has not yet been shown to spillover into humans, although rare cases of transient spillover have been documented for DENV1--DENV3 ([@bib48], [@bib50]).Figure 1Phylogenetic Relationship of DENV4 GenotypesDENV4 envelope protein sequences were aligned using neighbor-joining method with 100 replicates based on the multiple sequence alignment. Numbers in parentheses following virus species names indicate the number of sequences represented at that tree position.

In this manuscript, we used reverse genetics to generate a panel of recombinant DENV4 viruses that contain an isogenic backbone and differ only by the genotype sequence of the E protein. We used this panel of viruses to evaluate biological and virological properties associated with the E protein including its impact on neutralization using a well-characterized panel of human monoclonal antibodies, convalescent DENV4 sera, and vaccine sera from human volunteers. Our data reveal clear and significant antigenic differences among the DENV4 genotypes, which is critical for understanding immunity after natural DENV infection and evaluating vaccine responses.

Results {#sec2}
=======

Design of DENV4 Isogenic Envelope Panel {#sec2.1}
---------------------------------------

Phylogenetic analyses of DENV4 identifies six groups designated as genotypes I, IIa, IIb, III, IV (sylvatic), and V ([Figure 1](#fig1){ref-type="fig"}). As different isolates and genotypes of DENVs demonstrate variable growth rates and foci morphology in cell culture, hampering comparative studies of E protein variation, we used reverse genetics to construct a panel of recombinant DENV4 viruses. Using our previously described DENV4 molecular clone (genotype IIb) ([@bib18]), we replaced the wild-type (WT) envelope sequence with that from each of the other genotypes ([Table S1](#mmc1){ref-type="supplementary-material"}; [Figure 2](#fig2){ref-type="fig"}A). All other structural and non-structural proteins were derived from WT DENV4, resulting in an isogenic panel of viruses that only differ in the E gene sequence ([Figure 2](#fig2){ref-type="fig"}A). Sequence analyses across the DENV4 genotype viruses reveal significant amino acid variation in EDIII as well as residues adjoining the hinge region between EDI and EDII ([Figures 2](#fig2){ref-type="fig"}B, 2C, and [S1](#mmc1){ref-type="supplementary-material"}). When looking at the representative strain for each genotype, some amino acids differ in only one virus (e.g., position 132), whereas at other sites (e.g., position 351) the residues are variable across multiple genotypes ([Figures 2](#fig2){ref-type="fig"}B and 2C).Figure 2Design and Diversity of a Panel of DENV4 Genotypic Variants(A) Sequences encoding the envelope protein from each genotype were placed into a genotype IIb (WT) infectious clone, resulting in recombinant viruses that are entirely WT except for envelope protein, and sequence encoding envelope protein.(B) Envelope protein amino acids positions that differ from WT (genotype IIb).(C) Envelope protein amino acids that differ from WT are mapped on dimer based on number of genotypes differing at that position (PDB: [1OAN](pdb:1OAN){#intref0015}).

DENV4 Viruses Differ in Growth Kinetics and Foci Morphology {#sec2.2}
-----------------------------------------------------------

To recover recombinant viruses, full-length cDNAs were assembled as previously described ([@bib18], [@bib19]). Viruses were isolated by electroporating full-length infectious viral RNA into C6/36 cells, and passaging cell-culture supernatant once to produce infectious stocks. When C6/36 insect cells were infected in a multi-step viral growth curve (MOI of 0.01), all viruses replicated with similar kinetics and achieved similar peak titers of about 10^7^ ffu/mL after 4 days, with genotype IIa having slightly lower titers at earlier time points ([Figure 3](#fig3){ref-type="fig"}A). Growth curves performed at a higher MOI in C6/36 cells had similar growth kinetics across the panel, although viruses reached peak titers by day 3 post-infection ([Figure 3](#fig3){ref-type="fig"}A). The recombinant DENVs displayed more heterogeneous growth kinetics on Vero cells following both low and high MOI infections ([Figure 3](#fig3){ref-type="fig"}B). Genotype IIb viruses replicated most efficiently, and genotype V was significantly attenuated in growth, with peak titers 3 logs lower than that of the other genotypes ([Figure 3](#fig3){ref-type="fig"}B). While genotype V was highly attenuated in Vero cells, it was the only virus to cause complete syncytia in C6/36 cells ([Figure S2](#mmc1){ref-type="supplementary-material"}). Although speculative, it is possible that this demonstrates a virus adaptation for increased growth and spread in insect cells and insects. Syncytia formation has been seen with other strains of DENV ([@bib37]), but we did not observe syncytia with any of the other DENV4 genotype viruses.Figure 3DENV4 Genotype Viruses Differ in Growth and Foci Morphology(A and B) Viruses were analyzed for their ability to replicate in (A) C6/36 and (B) Vero cells at multiplicities of infection (MOI) of either 0.01 or 0.5 (mean ± SD of biological triplicates).(C--F) Viral foci were immunostained on both (C) C6/36 and (E) Vero cells, and average foci area for (D) C6/36 and (F) Vero cells were calculated using CTL ImmunoSpot analyzer software (mean ± SD of biological triplicates).

In addition to virus growth, we also compared viral foci morphology ([Figures 3](#fig3){ref-type="fig"}C--3F). C6/36 foci were similar across the entire panel ([Figures 3](#fig3){ref-type="fig"}C and 3D). Slightly more variation in foci morphology and size was noted in Vero cells across the panel, with genotype V producing the smallest foci; however, all strains produced foci that were clearly defined and visible ([Figures 3](#fig3){ref-type="fig"}E and 3F). The attenuated foci size of genotype V was consistent with reduced replication in Vero cell growth curves ([Figure 3](#fig3){ref-type="fig"}B).

DENV4 E Genotype Viruses Do Not Differ in Thermostability {#sec2.3}
---------------------------------------------------------

The large differences in viral replication of the DENV4 panel in mammalian and insect cells ([Figure 3](#fig3){ref-type="fig"}) may be a result of different temperature sensitivities, as studies have implicated envelope sequences and virion stability ([@bib30]). A thermostability assay revealed that the DENV4 variants are similarly stable, with little loss of infectivity after incubation at 28°C and 37°C; however, all viruses lost ∼1 log of infectivity after incubation at 40°C ([Figure 4](#fig4){ref-type="fig"}A). These results demonstrate that something other than thermostability contributes to differences in the ability of the viruses to infect and replicate in mammalian and insect cells.Figure 4DENV4 Genotype Viruses Differ in Thermostability, Maturation, and Glycosylation Status(A) DENV4 viruses were evaluated for their thermostability at 28°C, 37°C, and 40°C (mean ± SD of biological triplicates). Relative infectivity is calculated as (ffu/mL~test\ temperature~ / ffu/mL~4°C~) × 100.(B) Viruses were immunoblotted for envelope (E) and precursor (prM) protein present in viral stocks (representative image).(C) Binding assay using pr-specific mAb 1E16 to detect amount of pr protein present in virus stocks (mean ± SD of biological triplicates).(D) Antibody-dependent enhancement (ADE) assay was performed with DENV4 virus panel and anti-pr mAb 1E16 in U937 cells (mean ± SD of biological duplicates).(E) DENV envelope dimer showing location of putative pr interacting residues (navy) and glycosylation sites (yellow) (PDB: [1OAN](pdb:1OAN){#intref0020}).(F) Envelope and putative pr interacting sites (via side-chain interactions) are listed for each genotype.(G) Amino acid sequences of glycosylation sites 67 and 153 for each genotype. Genotype V lysine at amino acid position 153 (highlighted in red) disrupts glycosylation motif (N-X-T/S).

DENV4 E Variants Differ in Maturation Status, Enhanceability, and Glycosylation Pattern {#sec2.4}
---------------------------------------------------------------------------------------

As DENV maturation state may be heterogeneous *in vitro*, the recombinant panel allowed us to evaluate the role of E protein sequence on maturation status in an isogenic DENV4 backbone. During infection, DENV is assembled within the endoplasmic reticulum as immature virions containing pre-membrane (prM) proteins, which prevent fusion during viral egress. As DENV transits through the trans-Golgi network, pH change triggers cleavage of prM by the host protease furin. As the virus leaves the cell, cleaved pr dissociates, leaving fully mature viral particles. In cell culture, furin cleavage and pr dissociation are inefficient processes and highly cell type dependent, leading to heterogonous population of differentially mature viruses, containing different amounts of uncleaved pr peptide ([@bib38]). As maturation status can influence infectivity and antibody neutralization ([@bib35]), we compared the maturation status across the DENV4 panel using immunoblotting and ELISAs ([Figures 4](#fig4){ref-type="fig"}B and 4C).

Immunoblotting revealed that the levels of pr protein varied across the panel, with genotype I and III being the least mature (most pr present) and genotypes IV and V being the most mature (very little pr protein detected) ([Figure 4](#fig4){ref-type="fig"}B). To corroborate these findings using a different assay, ELISA binding assays were performed, by capturing DENV4 viruses with cross-reactive monoclonal antibodies (mAbs) 4G2 (anti-E) and 2H2 (anti-pr), then probing with a pr-specific antibody (1E16) ([@bib46]). These studies also demonstrated that there are differing levels of pr protein across the panel ([Figure 4](#fig4){ref-type="fig"}C). Consistent with immunoblotting, genotype III was highly immature, whereas genotype V was the most mature. As the DENV4 variant panel contains differing amounts of pr protein ([Figures 4](#fig4){ref-type="fig"}B and 4C), we sought to determine whether the viruses could be enhanced by a non-neutralizing, pr-specific mAb ([@bib46]). An antibody-dependent enhancement (ADE) assay revealed that despite differing levels of pr present on viruses, all viruses are similarly enhanced, although the concentration of antibody needed to achieve peak enhancement and the level of enhancement do vary across the viruses ([Figure 4](#fig4){ref-type="fig"}D).

The furin cleavage site (located in prM protein) was not altered across the panel, suggesting that the E protein sequence can impact virus maturation ([@bib38]). At a neutral pH of the released virus, the pr protein sits over the fusion-loop and is predicted to interact with seven amino acids in EDII ([Figures 4](#fig4){ref-type="fig"}E and 4F); however, at low pH, during processing of the virion, pr can make additional contacts across the envelope dimer. Under either condition, none of these amino acids were altered in the panel, suggesting that other residues may function to stabilize pr. Interestingly, there is little variability within the paired pr protein sequences of the variant panel ([Figure S3](#mmc1){ref-type="supplementary-material"}).

Immunoblotting also revealed that the envelope protein of genotype V is slightly smaller than that of the other genotypes ([Figure 4](#fig4){ref-type="fig"}B). The DENV envelope protein contains two glycosylation sites, one in EDII (Asn-67) and one in EDI (Asn-153) ([Figure 4](#fig4){ref-type="fig"}E). Analysis of the glycosylation site sequences across the panel revealed that a single amino acid change at residue 153 in genotype V disrupts the N-X-T/S glycosylation motif ([Figure 4](#fig4){ref-type="fig"}G), resulting in a smaller molecular weight envelope protein ([Figure 4](#fig4){ref-type="fig"}B). When looking at all genotype V viruses used in our phylogenetic tree ([Figure 1](#fig1){ref-type="fig"}; [Table S2](#mmc1){ref-type="supplementary-material"}), 87.5% have amino acid variability that disrupts the Asn-153 glycosylation site ([Table S3](#mmc1){ref-type="supplementary-material"}), suggesting this disrupted motif is not unique to the genotype V strain selected within our panel, but appears to be conserved across most genotype V viruses. DENV envelope glycosylation can be important for binding to host cell receptors, determining infectivity in different hosts, and binding and neutralization by antibodies ([@bib39], [@bib34], [@bib44]). Therefore, genotype V's conserved lack of the second glycosylation site might impact the virus's ability to efficiently infect and be transmitted between vertebrate and invertebrate hosts, and be the result of adaptation to a different cellular or host tropism ([@bib4], [@bib29]). Additionally, the lack of this glycosylation site might contribute to the genotype V C6/36 syncytia phenotype ([Figure S2](#mmc1){ref-type="supplementary-material"}). Genetic alteration of glycosylation and pr protein sequences, and generation of fully mature and fully immature virus preparations would allow one to determine the role of glycosylation and maturation status on many aspects of virus biology. Glycosylation status and large differences in viral maturation state have previously been shown to impact antibody binding and neutralization ([@bib35]); therefore, the binding and neutralization differences we see within this panel might be partially attributable to the variation in glycosylation and maturation.

Binding of Serotype-Specific and Cross-Reactive mAbs to DENV4 E Genotype Variants {#sec2.5}
---------------------------------------------------------------------------------

We next measured the binding of a panel of well-characterized DENV4 serotype-specific and DENV cross-reactive mAbs to our DENV4 viruses by ELISA ([Figure 5](#fig5){ref-type="fig"}). DENV4 serotype-specific antibodies D4-126 and D4-131 recognize partially overlapping epitopes that have not been fully defined in the EDI/II hinge region ([Figures S4](#mmc1){ref-type="supplementary-material"}A and S4B) ([@bib36]). All DENV4 genotypes bound similarly to D4-126 and D4-131 ([Figure 5](#fig5){ref-type="fig"}A). mAb D4-141, which recognizes an EDIII epitope ([Figure S4](#mmc1){ref-type="supplementary-material"}C), also bound all viruses similarly, despite large amount of variation in EDIII across the panel ([Figure 5](#fig5){ref-type="fig"}A). The non-human primate mAb 5H2, which binds to a well-defined epitope on EDI, displayed highly variable binding across the panel ([Figure 5](#fig5){ref-type="fig"}A). Two amino acids (162 and 174) predicted to be 5H2 contact residues were variable across the DENV4 panel ([Figure S4](#mmc1){ref-type="supplementary-material"}A) ([@bib9]). Genotype III did not bind 5H2 and contains an amino acid polymorphism at position 174, suggesting that this position is essential for 5H2 binding.Figure 5mAbs Differentially Bind DENV4 Genotype Viruses(A and B) DENV4 serotype-specific antibodies D4-126, D4-131, D4-141, and 5H2 (A) and DENV cross-reactive antibodies C10 and B7 (B) were evaluated for their ability to bind each virus at a range of antibody concentrations using ELISAs (mean ± SD of technical duplicates).

The cross-reactive human mAbs C10 and B7 recognize quaternary envelope dimer epitopes (EDEs) that span across the fusion loop of one E monomer into EDIII or EDI of the neighboring monomer ([Figures S4](#mmc1){ref-type="supplementary-material"}A and S4B) ([@bib44]). These mAbs bind all four DENV serotypes, reflecting the highly conserved nature of the epitope across the DENV E protein. Consequently, it was not surprising that C10 and B7 bound all genotypes within the DENV4 panel with similar efficiencies ([Figure 5](#fig5){ref-type="fig"}B), as the differences between genotypes are smaller than those between serotypes. Binding of B7, however, is dependent on the presence of a glycan at position 153 in EDI ([@bib44]). The DENV4 genotype V virus in this panel, which lacked this glycosylation site ([Figure 4](#fig4){ref-type="fig"}E), failed to bind to the B7 antibody ([Figure 5](#fig5){ref-type="fig"}B).

Neutralization of DENV4 E Genotype Variants by Serotype-Specific and Cross-Reactive mAbs {#sec2.6}
----------------------------------------------------------------------------------------

Next, we evaluated the ability of DENV4 serotype-specific and cross-reactive mAbs to neutralize the DENV4 panel in a Vero cell focus reduction neutralization test (FRNT), and a flow cytometry-based neutralization assay with U937 cells expressing DC-SIGN, a known DENV attachment factor ([Figures 6](#fig6){ref-type="fig"}A, [6](#fig6){ref-type="fig"}B, and [S5](#mmc1){ref-type="supplementary-material"}). We observed a 1- to 2-log difference in antibody neutralization titers of the DENV4 serotype-specific antibodies against the DENV4 panel. Importantly, some mAbs were not able to neutralize select genotypes even at the highest concentrations tested, despite robust binding (e.g., D4-126 and genotype III) ([Figures 5](#fig5){ref-type="fig"}A, [6](#fig6){ref-type="fig"}A, and 6B). Other mAbs have similar neutralization titers despite lower levels of binding (e.g., 5H2 and genotype V). These results reveal that, for each mAb and virus, the amount of mAb sufficient to bind and/or neutralize varies significantly.Figure 6DENV4 Genotypic Variants Are Differentially Neutralized by Monoclonal Antibodies(A and B) DENV4 serotype-specific antibodies D4-126, D4-131, D4-141, and 5H2 and DENV cross-reactive antibodies C10 and B7 were evaluated for their ability to neutralize DENV4 genotype viruses in (A) Vero cell focus reduction neutralization test (FRNT) and (B) flow cytometry-based neutralization assay (Neut) (mean ± SD of technical duplicates). The y-axes represent the concentration of antibody required to neutralize 50% of infectious virus. The dashed line represents assay limit of detection.

Consonant with the binding results, EDE mAbs C10 and B7 potently neutralize all viruses similarly ([Figures 6](#fig6){ref-type="fig"}A and 6B), with the exception of B7 and genotype V, due to its missing glycosylation site. The C10 and B7 epitopes are highly conserved across the DENV4 panel, likely explaining the robust and consistent neutralizing titers ([Figures S4](#mmc1){ref-type="supplementary-material"}A and S4B). Additionally, the range of neutralization titers is smaller for cross-reactive mAbs compared to serotype-specific mAbs, suggesting that the more cross-reactive an antibody is (i.e., the more serotypes it recognizes), the less genotypic diversity matters.

The Neutralization of DENV4 E Genotype Variant Viruses by Human Sera from Natural Infection and Vaccination {#sec2.7}
-----------------------------------------------------------------------------------------------------------

Convalescent immune sera from people who have recovered from primary DENV4 infections contain strongly neutralizing serotype-specific and weakly neutralizing cross-reactive antibodies. We performed neutralization assays with DENV4 convalescent immune sera to measure the breadth of neutralization across different DENV4 E variant genotypes ([Figures 7](#fig7){ref-type="fig"}A and [S6](#mmc1){ref-type="supplementary-material"}A). While the absolute neutralization titers vary across samples by 1--2 logs, all DENV4 immune sera were able to neutralize all genotypes ([Figure 7](#fig7){ref-type="fig"}A). While this suggests that natural infection with any DENV4 genotype elicits antibodies that are neutralizing against other genotypes as well, individuals who have weaker responses may be vulnerable to reinfection due to genotype variation.Figure 7DENV4 Polyclonal Immune Sera Have a Range of Neutralization Titers against DENV4 Variants Driven by Serotype-Specific Antibodies(A and B) Using Vero cell focus reduction neutralization test (FRNT), (A) pooled polyclonal immune sera from DENV4-infected non-human primates (NHPs) or from naturally infected individuals, or from (B) individuals who received the NIH DENV4 monovalent vaccine were evaluated for their ability to neutralize DENV4 genotype viruses.(C--F) DENV4 natural infection sera (C), DENV4 monovalent vaccine sera (D), and NIH DENV tetravalent vaccine sera were control depleted with BSA (E), or depleted of cross-reactive antibodies (F) and evaluated for their ability to neutralize DENV4 genotype viruses. The y axis represents the dilution factor of immune sera required to neutralize 50% of infectious virus (mean ± SD of technical duplicates). The dashed line represents one-half the assay limit of detection.

Individuals who received a genotype II DENV4 monovalent vaccine developed neutralizing antibodies ([Figures 7](#fig7){ref-type="fig"}B and [S6](#mmc1){ref-type="supplementary-material"}B). As seen with natural isolates ([@bib14]), we also observed a larger spread in neutralization titers with the monovalent vaccine immune sera (\>2 logs) compared to the natural infection sera. Additionally, for some vaccine sera, neutralizing antibodies were undetectable against some genotypes, despite robust neutralization of other strains (e.g., sample 68 does not neutralize genotype IV or V, but potently neutralizes genotype II viruses). Among the currently circulating genotype I, II, and III viruses, vaccine-matched genotype II viruses were most potently neutralized. To determine whether the differential genotype neutralization is driven by serotype-specific or cross-reactive antibodies, we used depletion techniques to specifically remove cross-reactive antibodies ([@bib12]) ([Figures 7](#fig7){ref-type="fig"}C, 7D, and [S6](#mmc1){ref-type="supplementary-material"}C--S6E). We find that removing cross-reactive antibodies minimally alters neutralization titers, suggesting that the majority of total neutralization comes from serotype-specific antibodies, and that the differences in titers across DENV4 genotypes are primarily driven by DENV4 serotype-specific antibodies as well.

We next looked at the DENV4 genotypic neutralizing breadth of individuals that received a tetravalent DENV vaccine. As tetravalent vaccination can result in both DENV4 serotype-specific antibodies, and strongly neutralizing cross-reactive antibodies, depletion techniques were again used to determine the contribution of each population of antibodies to total neutralization. Control depleted sera, containing both serotype-specific and cross-reactive antibodies, differentially neutralized the DENV4 variants, with vaccine-matched genotype II viruses neutralized on average 3- to 20-fold more efficiently than the other genotypes ([Figures 7](#fig7){ref-type="fig"}E and [S7](#mmc1){ref-type="supplementary-material"}A). In addition, some sera failed to neutralize currently circulating genotype I or III variants. When we removed DENV serotype cross-reactive antibodies, we observed only a small reduction in neutralization titers, indicating that the vaccine mainly induced serotype-specific neutralizing antibodies ([Figures 7](#fig7){ref-type="fig"}F and [S7](#mmc1){ref-type="supplementary-material"}B). Importantly, after removing cross-reactive antibodies, we see a similar spread in titers across the panel, suggesting that DENV4 serotype-specific antibodies are driving the differential genotypic neutralization. When all DENV cross-reactive and serotype-specific antibodies were depleted, we completely lost neutralization against all viruses ([Figure S7](#mmc1){ref-type="supplementary-material"}C).

Discussion {#sec3}
==========

DENV is the most significant arthropod-borne virus, causing significant morbidity and mortality worldwide. Sanofi-Pasteur's tetravalent DENV vaccine, Dengvaxia, has been marketed and used in human populations, and there are two additional commercial tetravalent vaccine candidates under evaluation in phase III human trials, including the NIH tetravalent DENV vaccine. Recent results with Dengvaxia demonstrate high vaccine efficacy in people who were dengue immune prior to vaccination (81.9%), and much poorer efficacy in people who were naive before vaccination (52.5%) ([@bib20]). Moreover, naive individuals who received the vaccine appear to be at greater risk of developing severe disease, when exposed to a natural DENV infection approximately 24 months or more following the last dose of vaccine. As a result, Dengvaxia is currently recommended only for use in people who have been primed by natural DENV infections ([@bib47]). Dengvaxia stimulated high levels of DENV4 serotype-specific neutralizing antibodies ([@bib22]), and overall vaccine efficacy was highest against DENV4. However, in subjects who experienced DENV4 breakthrough infections, molecular analyses indicated that the vaccine had a greater efficacy against vaccine-matched DENV4 genotype II than the co-circulating genotype I virus ([@bib40]). These data underscore the need for developing viruses and reagents that capture intra-serotype genetic variation when evaluating vaccine immune responses and identifying potential antibody-based correlates of protective immunity.

The existence of phylogenetically and antigenically distinct DENV1--DENV4 serotypes is well accepted in the literature ([@bib24]); however, the role of genetic diversity across genotypes is less well studied. Many common laboratory DENV strains have either been heavily cell culture adapted and/or differ in sequence from contemporary circulating strains ([@bib13], [@bib25], [@bib27]). Additionally, some laboratory, and importantly, vaccine strains, are composed of DENV genotypes that are likely extinct and, consequently, do not circulate in human populations ([@bib27]). While CD8^+^ T cells, CD4^+^ T cells, and other mechanisms of cellular immunity are correlated with DENV protective immunity ([@bib31]), and antibodies against DENV NS1 may also alter disease severity ([@bib23]), neutralizing antibodies represent the best correlate of protection to date ([@bib26], [@bib5]).

Natural DENV infection is thought to provide lifelong protection against symptomatic reinfection with that serotype ([@bib26], [@bib5]); however, it is unknown whether individuals are protected with the same efficacy against all genotypes within the serotype. There are reports of rare, typically asymptomatic, homotypic reinfection in people in Nicaragua and Peru ([@bib17], [@bib51]), which is potentially driven by genotypic differences between the primary and secondary infecting viruses. Some studies have evaluated the breadth of antibody neutralization against different genotypes elicited by natural infection or vaccination ([@bib3], [@bib14], [@bib25], [@bib32], [@bib49]). While most individuals exposed to natural infections or vaccines neutralized multiple genotypes within each serotype, absolute levels of neutralizing antibodies vary depending on the individual and the DENV genotypes used. Indeed, even in the current study, we noted that most individuals exposed to natural infections or a vaccine, developed antibodies that neutralized the most prevalent DENV4 genotypes, but the levels of neutralizing antibody varied considerably by genotype. In 2008, the World Health Organization (WHO) noted that there is little evidence of antigenic drift within DENV serotypes that might lead to resistance of certain strains to post-vaccination neutralization, yet they advised that laboratories consider inclusion of multiple virus strains, including laboratory prototype strains and recent clinical isolates when performing neutralization assays ([@bib42]). Our results demonstrate the value of including different DENV genotypes when evaluating vaccine responses.

Using reverse genetics, we developed an isogenic panel of DENV4 recombinant viruses that only differ in their E glycoprotein, which was derived from different genotypes. We reconstructed clinically relevant isolates with E protein genes derived from clinical specimens or low passage history in culture. Our data demonstrate that DENV4 E protein genotypic diversity can impact many aspects of the virus's cell biology including growth in cells, glycosylation, syncytial formation, and maturation. Additionally, as all the viruses can be enhanced, it highlights the importance of determining the impact of DENV genetic variation on disease enhancement after infection and vaccination. The chimeric DENV4 virus panel described here is a powerful tool for initial assessment of the impact of DENV E genotypic variation on virus biology and humoral immunity. As we selected one representative envelope sequence per genotype and utilized a recombinant approach, the viruses here do not capture all E protein sequence diversity within each genotype and some will never actually be encountered by vaccine recipients. Hence, it will be important to evaluate more contemporary DENV4 genotype I, II, and III strains in future studies, including the use of both natural and recombinantly derived isolates. In agreement with our findings, we note that another study using WT strains of endemic and sylvatic DENV4 viruses demonstrated better neutralization of vaccine-matched endemic genotype II viruses compared to sylvatic viruses using sera from DENV4 monovalent vaccine recipients ([@bib14]).

Our results demonstrate that infection or vaccination with a single DENV4 genotype stimulates variable levels of neutralizing antibodies to different genotypes. Currently, there are insufficient data to correlate levels of neutralizing antibodies to protection from DENV disease. Moreover, other immune mechanisms involving T cells, NS1 immunity, and B cell memory may also reduce or eliminate clinical disease ([@bib31]). However, it is worth noting that the licensed tetravalent DENV vaccine (Dengvaxia) had higher vaccine efficacy against vaccine-matched DENV4 genotype II (∼83%) viruses compared to co-circulating DENV4 genotype I viruses (∼47%) ([@bib40]). We propose that targeted surveillance of changing or emerging DENV genotypes following vaccination will be valuable in assessing the influence of DENV genotype on the frequency of repeat infections and overall vaccine effectiveness.

Experimental Procedures {#sec4}
=======================

Phylogenetic Tree {#sec4.1}
-----------------

The tree was constructed in Geneious R11 using the neighbor-joining method (Jukes--Cantor genetic distance) with 100 replicates based on the multiple sequence alignment. The radial phylogram was visualized and rendered for publication using CLC Sequence Viewer 7 and Adobe Illustrator CC 2017.

Virus Construction {#sec4.2}
------------------

Chimeric recombinant DENV4 viruses were constructed as described before ([@bib18], [@bib19]). Briefly, DNA encoding isogenic envelope protein sequences was introduced into a quadripartite DENV4 infectious clone system using synthetically derived genes and recombinant DNA approaches. Plasmid DNA was digested and ligated together, and viral full-length genomic RNA was generated using T7 RNA polymerase. Infectious genome-length capped viral RNA transcripts were electroporated into C6/36 cells, and supernatant was harvested and passaged onto C6/36 cells to make viral working stocks.

Cells {#sec4.3}
-----

C6/36 cells (ATCC CRL-1660) were grown in minimum essential medium (MEM) at 32°C. Vero cells (ATCC CCL-81) were grown in DMEM media, U937 and U937 cells stably expressing DC-SIGN (U937+DC-SIGN) were grown in RPMI medium 1640, and all were cultured at 37°C. All media were supplemented with 5% fetal bovine serum (FBS), which was reduced to 2% during DENV infection. All media were supplemented with 100 U/mL penicillin, 100 μg/mL streptomycin, and 0.25 μg/mL amphotericin B. C6/36 and U937/U937+DC-SIGN media were additionally supplemented with non-essential amino acids, and U937/U937+DC-SIGN media was further supplemented with [l]{.smallcaps}-glutamine and β-mercaptoethanol. All cells were incubated at 5% CO~2~.

Immune Sera {#sec4.4}
-----------

DENV4 immune non-human primate serum was obtained from BEI Resources (NR-41789). Human dengue immune sera were obtained from a previously described Dengue Traveler collection at the University of North Carolina. Vaccine sera were obtained from individuals who received a live-attenuated monovalent DENV4 or tetravalent vaccine 180 days post-vaccination, as developed by the NIH, and were provided by A.P.D. and S.S.W. All human sera samples were anonymized and obtained under Institutional Review Board approval.

Viral Titering and Immunostaining {#sec4.5}
---------------------------------

Cells were plated 1 day prior to infection. Growth media was removed, and virus stocks were serially diluted 10-fold, added to cells, and incubated for 1 hr at either 32°C (C6/36) or 37°C (Vero). After incubation, 1% methylcellulose in Opti-MEM (supplemented with 2% FBS, 100 U/mL penicillin, 100 μg/mL streptomycin, and 0.25 μg/mL amphotericin B) was overlaid, and cells were incubated for 3--4 days. Cells were washed with PBS and fixed with 80% methanol. Cells were blocked in 5% non-fat dried milk and stained with anti-E (4G2) and anti-prM (2H2) mAbs and horseradish peroxidase (HRP)-labeled secondary antibody. Foci were developed using TrueBlue substrate, and viral foci were counted manually.

Growth Curves {#sec4.6}
-------------

C6/36 or Vero cells were seeded in 24-well plates 1 day prior to infection. Viruses were diluted to an MOI of either 0.01 or 0.5, added to cells, and incubated for 1 hr at either 32°C (C6/36) or 37°C (Vero). Inoculum was removed, cells were washed three times with PBS, and growth media were replaced. Media were sampled daily, replaced with fresh media, and immediately frozen at −80°C. Samples were titered as described above.

Thermostability Assay {#sec4.7}
---------------------

DENV4 viruses were diluted 1:10, then incubated at 4°C, 28°C, 37°C, or 40°C for 1 hr, then immediately transferred to 4°C for 15 min. Viruses were then titered on Vero cells and immunostained as described above.

Immunoblotting {#sec4.8}
--------------

Virus stocks were diluted in PBS, mixed with sample buffer, and heated at 95°C for 10 min. Samples were run on 4%--20% Protean TGX gels and transferred to polyvinylidene difluoride (PVDF) membrane. Membranes were blocked in 5% non-fat dried milk and probed with anti-E (4G2) and anti-prM (1E16) mAbs. Membranes were washed and probed with secondary antibodies labeled with HRP and developed using chemiluminescent substrate. Membranes were visualized using a LI-COR C-DiGit Blot Scanner.

Enzyme-Linked Immunosorbent Binding Assay {#sec4.9}
-----------------------------------------

Plates were coated with anti-E (4G2) and anti-prM (2H2) antibodies in carbonate buffer overnight and blocked in 5% non-fat dried milk, and then virus antigen was added. Primary antibody was diluted in blocking buffer and added to plates for 1 hr at 37°C. Alkaline-phosphate-labeled secondary antibody was added and plates were incubated for 1 hr at 37°C. Plates were developed with p-nitrophenyl phosphate substrate and color changes were quantified using Bio-Rad iMark Microplate Absorbance Reader.

ADE Assay {#sec4.10}
---------

mAbs was diluted 5-fold and mixed with virus previously diluted to result in ∼15% infection in U937+DC-SIGN cells. Virus:mAb mixtures were incubated at 37°C for 45 min, and then added to 5 × 10^4^ U937 cells and incubated at 37°C for 2 hr. After incubation, cells were washed with growth media, and then resuspended in fresh growth media. The cells were incubated for 20 hr at 37°C, washed in PBS, fixed in 10% phosphate-buffered formalin, and then stained with anti-E mAb 4G2 directly conjugated to Alexa Fluor 488. Cells were analyzed on a Guava easyCyte flow cytometer.

Neutralization Assays {#sec4.11}
---------------------

FRNT was performed by seeding Vero cells 1 day prior to infection. mAbs or immune sera were diluted 4-fold and mixed with virus stocks previously diluted to ∼40 ffu/well. Virus:Ab mixtures were incubated at 37°C for 1 hr, and then added to cells for 1 hr at 37°C. After incubation, overlay media was added and plates were incubated for 3 days. Cells were fixed and immunostained as described as above. Flow cytometry-based neutralization assays were performed as described above in ADE assays, except with U937+DC-SIGN cells.

Polyclonal Antibody Depletion Assay {#sec4.12}
-----------------------------------

Dynabeads were covalently bound to anti-E mAb 1M7 overnight at 37°C. Bead:mAb complex was blocked with 1% BSA in PBS at 37°C, and then washed with 0.1 M 2-(*N*-morpholino)ethanesulfonic acid (MES) buffer. Beads were incubated with BSA (control), purified DENV3 (cross-reactive depletion), or a mix of DENV3 and DENV4 (full depletion) for 1 hr at 37°C, and then washed three times with PBS. Bead:mAb:DENV complex was fixed with 2% paraformaldehyde in PBS for 20 min, and then washed four times with PBS. DENV-specific antibodies were depleted from sera by incubating beads with sera diluted 1:10 in PBS for 1 hr at 37°C with end-over-end mixing for at least two sequential rounds of depletions. Removal of DENV antibodies was confirmed by ELISA.

Data Analysis and Software {#sec4.13}
--------------------------

All data were analyzed and graphed using GraphPad Prism v7.0a. Protein structures were visualized using MacPyMOL: PyMOL v1.7.6.2. Replicate information is included in the figure legends.

Supplemental Information {#app2}
========================

Document S1. Figures S1--S7 and Tables S1--S3Document S2. Article plus Supplemental Information

This research was supported by National Institute of Allergy and Infectious Diseases (NIAID) grants R01s AI107731 (principal investigator \[PI\], A.M.d.S.) and AI125198 (PI, A.M.d.S.), P01 AI106695 (PI, E. Harris), and U19 AI109761 (PI, R.S.B.) and by grant OPP1104710 from the Bill and Melinda Gates Foundation (PI, A.P.D.). Support was also provided in part by the Intramural Research Program of the NIAID. E.N.G. was supported by T32 NIH Training Grant AI007419. We thank Stephanie Marcet, Scott Royal, and Prem Lakshmanane for assistance.

Author Contributions {#sec5}
====================

Conceptualization, E.N.G., A.M.d.S., and R.S.B.; Investigation, E.N.G., T.J.B, U.N., M.J.D., R.G., D.G.W., and B.L.Y.; Resources, A.P.D., S.S.W., A.M.d.S., and R.S.B.; Writing -- Original Draft, E.N.G.; Writing -- Review & Editing, E.N.G., A.P.D., S.S.W., A.M.d.S., and R.S.B.; Supervision, A.M.d.S. and R.S.B.

Declaration of Interests {#sec6}
========================

A.M.d.S. has consulted on dengue vaccines for Takeda, Merck, and GSK. R.S.B. has consulted with Takeda on vaccines. A.M.d.S. and R.S.B. are inventors on patents filed and issues relevant to dengue vaccines.

Supplemental Information includes seven figures and three tables and can be found with this article online at [https://doi.org/10.1016/j.celrep.2018.10.006](10.1016/j.celrep.2018.10.006){#intref0010}.

[^1]: Lead Contact
